Recursion Pharmaceuticals Files 8-K

Ticker: RXRX · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1601830

Recursion Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyRecursion Pharmaceuticals, Inc. (RXRX)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.00001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, filing

Related Tickers: RXRX

TL;DR

RXRX filed a routine 8-K, no major news.

AI Summary

Recursion Pharmaceuticals, Inc. filed an 8-K on January 13, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond standard reporting requirements.

Why It Matters

This 8-K filing serves as a routine update and does not appear to contain significant new information that would immediately impact the company's stock price.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for Regulation FD disclosure and exhibits, with no indication of material adverse events or significant new developments.

Key Players & Entities

  • RECURSION PHARMACEUTICALS, INC. (company) — Registrant
  • January 13, 2025 (date) — Date of earliest event reported
  • 001-40323 (company) — Commission File Number
  • 464099738 (company) — I.R.S. Employer Identification No.
  • 41 S Rio Grande Street (location) — Address of principal executive offices
  • Salt Lake City, UT 84101 (location) — City, State, Zip code of principal executive offices

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is January 13, 2025.

What is Recursion Pharmaceuticals, Inc.'s Commission File Number?

Recursion Pharmaceuticals, Inc.'s Commission File Number is 001-40323.

Where are Recursion Pharmaceuticals, Inc.'s principal executive offices located?

Recursion Pharmaceuticals, Inc.'s principal executive offices are located at 41 S Rio Grande Street, Salt Lake City, UT 84101.

Does this filing indicate any new material agreements or events?

The filing indicates it is for Regulation FD Disclosure and Financial Statements and Exhibits, but does not specify any new material agreements or events beyond these categories.

Filing Stats: 514 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2025-01-13 09:04:33

Key Financial Figures

  • $0.00001 — stered Class A Common Stock, par value $0.00001 per share RXRX Nasdaq Global Select Mar

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On January 13, 2025, Recursion Pharmaceuticals, Inc. (the "Company") released an updated investor presentation. The investor presentation will be used at the JP Morgan Healthcare Conference and from time to time in meetings with investors. A copy of the presentation is attached hereto as Exhibit 99.1. The information furnished in this Item 7.01 (including Exhibit 99.1), shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Investor Presentation of Recursion Pharmaceuticals, Inc. dated January 13, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on January 13, 2025. RECURSION PHARMACEUTICALS, INC. By: /s/ Christopher Gibson Christopher Gibson Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.